CCME Global Ltd (514336)

Healthcare · Healthcare · NSE · Updated 2 September 2026

By StockFin Research Team • AI-Assisted Analysis • Source: BSE/NSE Filings

₹35.91 ↓ 5.6% (1Y)

🎯 Key Takeaways

CCME Global Ltd is in a strategic transformation phase, actively pursuing expansion into FMCG and distribution markets in the Middle East and UAE through targeted acquisitions, funded by a proposed preferential issue and stock split. The company has shifted focus from minimal operations to growth initiatives, though financial performance remains weak with persistent losses and near-zero revenue.
⚠️ 1) High dilution risk from the proposed INR 180 crore preferential issue at a 90% discount to market sentiment, which could erode existing shareholder

Market Cap

₹162

P/B Ratio

16.94

ROE

-8.8%

ROCE

-8.8%

Debt/Equity

0.01

Promoter

74.3%

✨ Ask AI About 514336 📊 Interactive Charts

📖 The Story

CCME Global Ltd is in a strategic transformation phase, actively pursuing expansion into FMCG and distribution markets in the Middle East and UAE through targeted acquisitions, funded by a proposed preferential issue and stock split. The company has shifted focus from minimal operations to growth initiatives, though financial performance remains weak with persistent losses and near-zero revenue. It is currently in a capital-intensive investment phase, prioritizing market entry over profitability.

📰 What's Happening

In the August 29, 2026 board meeting, CCME Global approved the acquisition of 52% of Interlink Distribution LLC for INR 20.34 crores and over 50% of Cash & Carry Middle East FZCO for INR 127.73 crores, funded partly by a proposed INR 180 crore preferential issue of 1.8 million shares at INR 10 each. The board also amended the memorandum of association to relocate the registered office from Andhra Pradesh to Maharashtra and increase authorized capital. These moves signal a strategic pivot into Middle Eastern distribution networks, with transactions pending RBI approval under FEMA regulations.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	0	0	0	0	0
Operating Profit	-0	-0	-0	-1	-0
OPM %	—	—	—	-1250.0%	—
Net Profit	-0	-0	-0	-1	-0
EPS	₹-0.09	₹-0.05	₹-0.02	₹-0.37	₹-0.06

Quarterly financials show a consistent pattern of zero revenue and recurring losses since September 2025, with net loss widening to ₹1 crore in March 2026 from ₹0.02 crore in December 2025, indicating escalating operational drag despite no revenue generation. The absence of any operational turnover suggests the company is currently in a pre-revenue investment stage, where financial outflows are expected but not yet offset by commercial activity.

🔮 Management Outlook & What's Next

Management has not provided forward guidance on revenue recovery, margin improvement, or timeline for profitability in recent filings. The focus remains on execution of acquisitions and capital restructuring, with no disclosed targets for operational breakeven or cash flow positivity. The lack of commentary on business recovery or performance metrics suggests limited visibility into near-term financial turnaround.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

Item	Mar 2018
Equity Capital	13
Reserves	-3
Borrowings	0
Total Liabilities	12
Fixed Assets	2
Investments	0
Total Assets	12

The balance sheet as of March 2018 shows minimal equity (₹13 crore) and no liabilities, but this outdated snapshot does not reflect current capital structure changes. The proposed INR 180 crore preferential issue would significantly increase equity base and dilute existing shareholders, signaling aggressive capital mobilization to fund acquisitions. No evidence of deleveraging or asset sales, indicating investment-driven balance sheet expansion.

💰 Cash Flow Statement (₹ Cr)

Item	Mar 2018
Operating	+2
Investing	-5
Financing	+3
Net Cash Flow	+0

👥 Shareholding Pattern

Category	Q3FY26	Q4FY26	Q1FY27
Promoters	11.3%	74.2%	74.3%
FII	0.0%	0.0%	0.0%
DII	0.0%	0.0%	0.0%
Public	25.1%	25.1%	9.7%
# Shareholders	1,855	1,938	1,937

Promoter holding has declined sharply from 74.35% in Q1FY27 to 11.33% in Q3FY26, while public shareholding rose from 25.08% to 25.07% during the same period, suggesting promoter stake reduction may be linked to capital raising. FII and DII holdings remain negligible (0%), indicating limited institutional interest. The growing number of shareholders (1,855 to 1,938) reflects retail participation but no significant foreign investor accumulation.

⚖️ Peer Comparison — Healthcare

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
APOLLOHOSP	1.26 L Cr	60.3	22.1%	22.9%	0.60
MANIPALHOS	98,259	—	—	—	1.25
MAXHEALTH	98,006	67.2	14.4%	13.6%	0.27
FORTIS	68,769	65.6	13.3%	10.8%	0.29
ASTERDM	66,090	122.7	17.2%	11.9%	0.21
NH	39,605	48.2	13.7%	18.0%	1.07
MEDANTA	39,163	70.4	21.9%	16.3%	0.10
LALPATHLAB	31,910	45.9	29.6%	21.8%	0.00
KIMS	31,878	148.8	9.7%	8.7%	1.44
POLYMED	17,790	56.5	15.1%	11.3%	0.06

🔗 Peer Stock Analyses

APOLLOHOSP MANIPALHOS MAXHEALTH FORTIS ASTERDM

⚠️ Risk Factors

1) High dilution risk from the proposed INR 180 crore preferential issue at a 90% discount to market sentiment, which could erode existing shareholder value. 2) Acquisitions are contingent on RBI approval under FEMA, introducing regulatory uncertainty with no disclosed timeline for clearance. 3) Prolonged pre-revenue status with worsening losses and zero revenue since 2025 raises concerns about funding sustainability. 4) Lack of operational traction or revenue generation despite multiple strategic announcements over several quarters.

📋 Recent Filings

🧠 Analyst's Read

CCME Global is undergoing a high-risk strategic shift into Middle Eastern distribution markets, funded by shareholder dilution and pending regulatory approvals, with no evidence of revenue generation or path to profitability. Investors should monitor RBI approval status for acquisitions and the utilization of capital raised through the preferential issue, as execution delays or operational failures could further strain financials.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on 514336

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-02.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts for your stocks — summarized by AI daily

Set up your AI Radar — pick stocks, get daily email summaries of new filings.

Set up AI Radar — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd